How will the latest updates on GLP-1 supply and Rybelsus prescription guidelines impact your practice? With diabetes affecting over 4 million people in the UK, staying abreast of the latest treatment protocols is crucial for healthcare professionals. The Department of Health and Social Care has recently issued new guidelines that could significantly influence how you prescribe GLP-1 receptor agonists, particularly Rybelsus®.
These updates are not just administrative changes; they are designed to optimise patient outcomes and ensure the sustainability of essential medications. From transitioning patients from injectable forms like Byetta® and Victoza® to oral Rybelsus® tablets, to implementing shared decision-making in treatment plans, these guidelines are comprehensive.
Read more to understand the key actions you need to take by March 28, 2024, and how these changes can enhance your practice and patient care.
Key Takeaways
What are GLP-1 Receptor Agonists?
GLP-1 receptor agonists (RAs) are a class of medications used primarily in the management of type 2 diabetes. They work by mimicking the action of the glucagon-like peptide-1 hormone, which increases insulin secretion, inhibits glucagon release, and slows gastric emptying. This helps to regulate blood sugar levels more effectively.
Commonly Used GLP-1 RAs
Some of the commonly prescribed GLP-1 RAs include:
Byetta® (exenatide): An injectable medication taken twice daily.
Victoza® (liraglutide): An injectable medication taken once daily.
Rybelsus® (semaglutide): An oral tablet taken once daily.
New Prescription Guidelines
Prescribe GLP-1 RAs Strictly for Licensed Indications
Healthcare professionals are now required to prescribe GLP-1 RAs strictly for their licensed indications. This ensures that these medications are used appropriately and effectively, reducing the risk of off-label use that may not be supported by clinical evidence.
Initiate New GLP-1 RA Treatments with Rybelsus® Tablets
According to the NICE NG28 guidelines, new GLP-1 RA treatments should be initiated with Rybelsus® tablets. This oral formulation offers a convenient alternative to injectable options, potentially improving patient adherence and satisfaction.
Transitioning Patients to Rybelsus® Tablets
Healthcare professionals are advised to transition patients currently on Byetta® and Victoza® injections to Rybelsus® tablets. This aligns with the NICE NG28 guidelines and aims to streamline treatment protocols, making it easier for patients to manage their medication.
Patient Education and Communication
Importance of Educating Patients
It is crucial to educate patients about any changes in their medication, formulation, or dosage. This helps ensure they understand the reasons for the changes and how to take their new medication correctly.
Strategies for Effective Patient Communication
Use Clear and Simple Language: Avoid medical jargon and explain changes in a way that is easy to understand.
Provide Written Instructions: Give patients written instructions to refer to at home.
Encourage Questions: Make sure patients feel comfortable asking questions about their new treatment.
Tools and Resources for Patient Education
Patient Information Leaflets: Provide detailed information about the new medication.
Educational Videos: Use videos to demonstrate how to take the new medication.
Support Groups: Encourage patients to join support groups where they can share experiences and get advice.
Reviewing and Managing Current Patients
Stopping GLP-1 RA if Treatment Goals Aren't Met
According to NICE NG28/CG189 guidelines, if treatment goals are not met, it may be necessary to stop GLP-1 RA therapy. Regularly review patients to assess whether their treatment goals are being achieved.
Avoiding Dosage Doubling
When higher doses of GLP-1 RAs are unavailable, avoid doubling the dosage. This can lead to adverse effects and does not necessarily improve treatment outcomes.
Not Switching Strengths Based Solely on Availability
Do not switch the strength of GLP-1 RAs based solely on availability. This can lead to confusion and potential dosing errors. Always consult with the patient and consider clinical advice before making any changes.
Prescribing Responsibly
Prescribe GLP-1 RAs responsibly to protect supply chains and ensure that all patients have access to the medication they need. This includes avoiding over-prescription and ensuring that prescriptions are for licensed indications only.
Shared Decision-Making and Alternative Treatments
Importance of Shared Decision-Making
Shared decision-making involves the patient in the treatment planning process. This ensures that their preferences and values are considered, leading to better adherence and satisfaction with the treatment.
Overview of Alternative Treatments
When GLP-1 RAs are not suitable, consider alternative treatments such as:
Metformin: Often the first-line treatment for type 2 diabetes.
SGLT2 Inhibitors: Help to lower blood sugar by causing the kidneys to remove sugar from the body through urine.
DPP-4 Inhibitors: Help to increase insulin production and decrease the amount of glucose produced by the liver.
Clinical Advice for Selecting Alternative Treatments
When selecting alternative treatments, consult clinical guidelines and consider the patient's medical history, preferences, and treatment goals. Always involve the patient in the decision-making process.
Encouraging Patient Participation
Importance of Patient Participation
Encouraging patients to participate in education and weight management programs can significantly improve their long-term diabetes management. These programs provide valuable information and support, helping patients to make healthier lifestyle choices.
Benefits of Education and Weight Management Programs
Improved Blood Sugar Control: Education programs teach patients how to manage their blood sugar levels effectively.
Weight Loss: Weight management programs can help patients to lose weight, which can improve their diabetes control.
Support and Motivation: These programs provide a support network and motivation to help patients stay on track with their treatment.
How to Encourage Patient Involvement
Provide Information: Give patients information about available programs and how they can benefit from them.
Offer Support: Offer support and encouragement to help patients get started and stay committed.
Follow Up: Regularly follow up with patients to check on their progress and provide additional support if needed.
Conclusion
It is crucial for healthcare professionals to stay informed about the latest updates on GLP-1 supply and Rybelsus prescription guidelines. By adhering to these new guidelines, you can optimise patient outcomes, ensure the sustainability of essential medications, and enhance your practice.
At The Medicines Management Team (TMMT), our experienced team of advanced clinical practitioners and GPs can help your practice or PCN deliver efficient medicines management services. Partner with TMMT to reduce the strains within primary care.
Contact us today to learn more.
FAQs
Is there a supply shortage for Rybelsus?
Currently, there is no reported supply shortage for Rybelsus. However, it is always advisable to prescribe responsibly to ensure the medication's sustainability for all patients.
Are Ozempic and Rybelsus interchangeable?
Is Rybelsus available on the NHS?
How can I get a GLP-1 prescription?
댓글